- Home
- TBI vs ARMP Comparison
TBI vs ARMP Comparison
Compare TBI & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TBI | ARMP |
|---|---|---|
| Founded | 1985 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.9M | 125.7M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | TBI | ARMP |
|---|---|---|
| Price | $4.41 | $6.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 211.7K | 35.0K |
| Earning Date | 02-18-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,583,772,000.00 | $5,054,000.00 |
| Revenue This Year | $3.80 | $4.48 |
| Revenue Next Year | $5.04 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.45 | $0.90 |
| 52 Week High | $8.56 | $16.34 |
Technical Indicators
Market Signals| Indicator | TBI | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 34.10 | 56.69 |
| Support Level | $4.47 | $6.08 |
| Resistance Level | $4.78 | $6.60 |
| Average True Range (ATR) | 0.18 | 0.47 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 5.64 | 99.36 |
Price Performance
Historical ComparisonAbout TBI TrueBlue Inc.
TrueBlue Inc is a provider of staffing and workforce management solutions. Its reportable segments include PeopleReady offers industrial staffing services. PeopleManagement offers contingent and productivity-based on-site industrial staffing services and PeopleScout offers recruitment process outsourcing, talent advisory services, and managed service provider services. It generates maximum revenue from the PeopleReady segment.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.